Clinical trials: Post-menopausal Women
Advanced Breast Cancer
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
- Trial name
- NCT02069093
- Testing
- Dexamethasone based mouthwash, Everolimus, Exemestane
- Where
- 23 sites in United States
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Open Label Extension Study of PREOS
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human…
- Trial name
- OLES (NCT00172133)
- Testing
- ALX1-11 (drug)
- Where
- 132 sites in United States, Argentina and 6 more
- Volunteers
- 1,683 people
- Sponsor
- Shire
Breast Cancer
Patient's Anastrozole Compliance to Therapy Programme
Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS).
- Trial name
- PACT (NCT00555867)
- Testing
- Anastrozole
- Volunteers
- 4,923 people
- Sponsor
- AstraZeneca
Healthy
Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)
This is a Phase I, open label, dose escalation study designed to evaluate the pharmacokinetics, safety, and tolerability of single intramuscular injections of Letrozole ISM® at different strengths in voluntary healthy post…
- Trial name
- NCT03401320
- Testing
- Letrozole ISM
- Where
- Czechia
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Menopause, Hypertension
Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women
ACE inhibitors are thought to modify the endothelium in a number of ways. Quinapril is an effective and well-tolerated ACE-I for the treatment of patients with hypertension and congestive heart failure.
- Trial name
- NCT00147524
- Testing
- quinapril, Laser Doppler imaging
- Where
- 5 sites in Hungary
- Volunteers
- 70 people
- Sponsor
- Pfizer
Dehydration, Menstruation
Hydration & Female Life Stages
Female life stages including premenopausal, perimenopausal, postmenopausal, are characterized by changing concentrations and patterns of hormones.
- Conditions
- Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women
- Trial name
- NCT07653620
- Testing
- electrolyte beverage
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Postmenopausal Osteoporosis
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
- Trial name
- NCT00293813
- Testing
- Alendronate, Denosumab
- Volunteers
- 247 people
- Sponsor
- Amgen
Advanced Breast Cancer (Female)
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).
- Trial name
- NCT02142868
- Testing
- Palbociclib, Letrozole
- Where
- 55 sites in United States, Canada
- Sponsor
- Pfizer
Postmenopausal Osteoporosis
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis.
- Trial name
- NCT02598440
- Testing
- Alendronate, Ibandronate
- Where
- 54 sites in United States
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche